Glycemic control among patients with type 2 diabetes who initiate basal insulin: A retrospective cohort study

Journal of Medical Economics

Volumn 17, Issue 1, 2014, Pages 21-31

  Curtis, Bradley ^a   Lage, Maureen J ^b  

^a ELI LILLY AND COMPANY   (United States)

^b HealthMetrics Outcomes Research   (United States)

Author keywords

Basal insulin; Diabetes; Electronic medical records database; Glycemic control; Type 2

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEPRESSION; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; END STAGE RENAL DISEASE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INCOME; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL RECORD REVIEW; MEDICALLY UNINSURED; MEDICARE; MIDDLE AGED; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; UNITED STATES; YOUNG ADULT;

ABSENTEEISM; BLOOD GLUCOSE; CANADA; DIABETES MELLITUS, TYPE 2; EMPLOYMENT; FEMALE; GLYCEMIC INDEX; HEALTH SERVICES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; QUALITATIVE RESEARCH; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 84890452549     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.862538     Document Type: Article

References (66)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
2. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
4. Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med 2010;123:374.e 9-18
5. Home P, Mant J, Diaz J, et al; Guideline Development Group. Management of type 2 diabetes: summary of updated NICE guidance. BMJ 2008;336:1306-8
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
7. National Institute for Clinical Excellence: NICE. Management of Type 2 Diabetes. London: NICE, 2002
8. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
9. Holt RIG. Insulin initiation in Type 2 diabetes: the implications of the 4-T study. Diabet Med 2010;27:1-3
10. Hajos TRS, Pouwer F, de Grooth R, et al. Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. Diabet Med 2011;28:1096-102
11. Goodall G, Sarpong EM, Hayes C, et al. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord 2009;9:19
12. Blak BT, Smith HT, Hards M, et al. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012;29:e13-20
13. Pollock RF, Erny-Albrecht KM, Kalsekar A, et al. Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. Curr Diabetes Rev 2011;7:61-74
14. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in Type 2 Diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia Care 2012;35:1364-79
15. Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors' expert forum. Diabetes Care 2013;36:1779-88
16. Institute of Medicine (IOM). Crossing the quality chasm: a new health system for the 21st Century. Washington, DC: The National Academy Press, 2001
17. Smith RJ, Nathan DM, Arslanian SA, et al. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010;95:1566-74
18. Clarke EJ, Barton BA. Entropy and MDL discretization of continuous variables for Bayesian belief networks. Int J Intel Syst 2000;15:61-92
19. Fogelfeld L, Dharmalingam M, Robling K, et al. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. Diabet Med 2010;27:181-8
20. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
22. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-7
23. Bretzel RG, Eckhard M, Landgraf W, et al. Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents. Diabetes Care 2009;32(2 Suppl):S260-5
24. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabeteic patients. Diabetes Care 2003;26:3080-6
25. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial therapy for type 2 diabetes. Diabetes Care 2005;28:254-9
26. Healthcare.gov. Key Features of the Affordable Care Act by Year. US Department of Health & Human Services. http://www.hhs.gov/healthcare/ facts/timeline/timeline-text.html
27. Executive summary: Standards of medical care in diabetes-2013. Diabetes Care 2013;36(1 Suppl):S4-S10
28. Munshi MN, Pandya N, Umpierrez GE, et al. Contributions of basal and prandial hyperglycemia to total hyperglycemia in older and younger adults with type 2 diabetes mellitus. J Am Geriatr Soc 2013;61:535-41
29. Egan BM, Shaftman SR, Wagner CS, et al. Demographic differences in the treatment and control of glucose in type 2 diabetic patients: implications for health care practice. Ethn Dis 2012;22:29-37
30. Hessler DM, Fisher L, Mullan JT, et al. Patient age: a neglected factor when considering disease management in adults with type 2 diabetes. Patient Educ Couns 2011;85:154-9
31. Tirosh A, Stern Z, Mazar M, et al. The influence of age on the management of patients with diabetes in the Israeli population. Popul Health Manag 2013;16:276-82
32. Ahluwalia IB, Mack KA, Murphy W, et al. State-specific prevalence of selected chronic disease-related characteristics-Behavioral Risk Factor Surveillance System, 2001. MMWR Surveill Summ 2003;52:1-80
33. Best JD, Drury PL, Davis TME, et al; Fenofibrate Intervention and Event Lowering in Diabetes Study Investigators. Glycemic control over 5 years in 4900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care 2012;35:1165-70
34. Ott P, Benke I, Stelzer J, et al. ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. Dtsch Med Wochenschr 2009;134:291-7
35. O'Connor PJ, Asche SE, Craine AL, et al. Is patient readiness to change a predictor of improved glycemic control? Diabetes Care 2004;27: 2325-9
36. Ali MK, McKeever Bullard K, Imperature Barker L, et al. Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes - National Health and Nutrition Examination Survey, United States, 2007-2010. MMWR Morb Mortal Wkly Rep 2012;61: Suppl:32-37
37. American Diabetes Association. Living with diabetes: tight diabetes control. Alexandria, VA: American Diabetes Association (ADA). July 16, 2003. http:// www.diabetes.org/living-with-diabetes/treatment-and-care/blood- glucosecontrol/ tight-diabetes-control.html. Accessed 13 Oct 2013
38. The ORIGIN Trial Investigators. Characteristics associated with maintenance of mean A1C56.5% in people with dysglycemia in the ORIGIN Trial. Diabetes Care 2013;10:2915-22
39. Centers for Disease Control and Prevention. Diabetes Report Card 2012. Atlanta, GA: Centers for Disease Control and Prevention, 2012. p 1-14
40. Barker LE, Kirtland KA, Gregg EW, et al. Geographic Distribution of Diagnosed Diabetes in the U.S. Am J Prev Med 2011;40:434-9
41. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-200
42. Mendes E. Wellbeing: Hawaii Tops Utah for Nation's Best. 2010. Washington DC: Gallup. www.gallup.com/poll/125849/hawaii-tops-utah-nation-best. aspx. Accessed 13 Oct 2013
43. Page S. Western cities fare best in well-being index. USA Today, 2010 McLean, VA. usatoday30.usatoday.com/news/nation/2010-02-15-cities-N. htm. Accessed February 15, 2010
44. Mayer-Davis EJ, Costacou T. Obesity and sedentary lifestyle: modifiable risk factors for prevention of type 2 diabetes. Curr Diab Rep 2001;1:170-6
45. Healy GN, Dunstan DW, Salmon J, et al. Breaks in sedentary time beneficial associations with metabolic risk. Diabetes Care 2008;31:661-6
46. Ivy DJL. Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. Sports Med 1997;24:321-36
47. Egede LE, Gebregziabher M, Hunt KJ, et al. Regional, geographic, and racial/ ethnic variation in glycemic control in a national sample of veterans with diabetes. Diabetes Care 2011;34:938-43
48. Cummings DM, Lutes LD, Littlewood K, et al. EMPOWER: a randomized trial using community health workers to deliver a lifestyle intervention program in African American women with Type 2 diabetes: design, rationale, and baseline characteristics. Contemp Clin Trials 2013;36:147-53
49. Wendel CS, Shah JH, Duckworth WC, et al. Racial and ethnic disparities in the control of cardiovascular disease risk factors in Southwest American veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study. BMC Health Serv Res 2006;6:58
50. Hunt KJ, Gebregziabher M, Lynch CP, et al. Impact of diabetes control on mortality by race in a national cohort of veterans. Ann Epidemiol 2013;23:74-9
51. Nichols GA, Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614-9
52. Cosmi F, Cosmi D, Savino K, et al. [Insulin therapy may hasten congestive heart failure in cardiac patients: case series and review of the literature]. G Ital Cardiol (Rome) 2008;9:509-12
53. Rajagopalan R, Rosenson RS, Fernandes AW, et al. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 2004;26:1400-10
54. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
55. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
56. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-39
57. Siraj E, Rubin D, Miller M. The relationship between insulin exposure and cardiovascular mortality in the ACCORD trial. Presented at the American Diabetes Assocation, 73rd Scientific Sessions, Chicago, IL: 2013, Abstract:386-OR. http://www.abstractsonline.com/Plan/ViewAbstract.aspx? sKey=cc61c947-010f-409e-98f9-fdfd0339ffa7&cKey=53683283-141d- 47f7-921d-3c56faab197f&mKey={89918D6D-3018-4EA9-9D4F-711F98 A7AE5D}#. Accessed 13 Oct 2013
58. Wood S. Aggressive glucose control no benefit in CV surgery patients with T2D. theheart.org, 2013. New York. http://www.staging.iad1.theheart.org/ article/1556399.do. Accessed June 26, 2013
59. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes an update. Diab Care 2004;27: 1879-84
60. Fabricatore AN, Wadden TA. Treatment of obesity: an overview. Clin Diabetes 2003;21:67-72
61. Shani M, Taylor TR, Vinker S, et al. Characteristics of diabetics with poor glycemic control who achieve good control. J Am Board Fam Med 2008;21:490-6
62. Berkowitz SA, Baggett TP, Wexler DJ, et al. Food insecurity and metabolic control among U.S. Adults With Diabetes. Diabetes Care 2013;36: 3093-9
63. Seligman HK, Jacobs EA, López A, et al. Food insecurity and glycemic control among low-income patients with type 2 diabetes. Diabetes Care 2012;35:233-8
64. Barnett A. Dosing of insulin glargine in the treatment of type 2 diabetes. Clin Ther 2007;29:987-99
65. Garber AJ. Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab 2013. doi:10.1111/dom12129
66. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National clinical guideline for management in primary and secondary care (update). London (UK): Royal College of Physicians. 2008. http://www. nice.org/uk/nicemedia/pdf/CG66diabetesfullguideline.pdf. Accessed 13 Oct 2013